

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number  
**WO 2005/005384 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 207/34**

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/TR2003/000062

**Declarations under Rule 4.17:**

(22) International Filing Date: 15 July 2003 (15.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **EOS ECZACIBASI OZGUN KIMYASAL URUNLER SANYI VE TICARET A.S.** [TR/TR]; Buyukdere Caddesi, Ali Kaya Sokak, N°7, Levent,, 34394, Istanbul (TR).

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DABAK, Kadir** [TR/TR]; Buyukdere Caddesi, Ali Kaya Sokak No. 7, 34394 Levent, Istanbul (TR). **KESKIN, Hulya** [TR/TR]; Buyukdere Caddesi, Ali Kaya Sokak No. 7, 34394 Levent, Istanbul (TR).

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(74) Agent: **SEVINC, Erkan**; ISTANBUL PATENT & TRADEMARK CONSULTANCY LTD., Büyükdere cad. Gün apt. No:26/16 Mecidiyeköy, 80290 Istanbul (TR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

— of inventorship (Rule 4.17(iv)) for US only

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM WITHOUT INTERCONVERSION OF ANY CRYSTALLINE FORM

(57) Abstract: The invention relates to a novel process for the preparation of amorphous atorvastatin calcium salt (2:1) from atorvastatin tert-butyl ester (Figure 1). The preparation comprises: (a) dissolving atorvastatin tert-butyl ester (Figure 1) in a solvent, (b) adding an aqueous alkaline or alkaline earth metal hydroxide solution, (c) removing of the solvent, b) adding water and a water non soluble solvent, e) adding an aqueous calcium salt solution, f) separation of the phases and removing of the solvent to obtain desired amorphous atorvastatin calcium and hydrates thereof. The process disclosed herein gives amorphous form directly without interconversion of any crystalline form into amorphous form.



WO 2005/005384 A1

PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM WITHOUT INTERCONVERSION OF ANY CRYSTALLINE FORM

The accompanying drawings show as follows:

Fig.1 shows the formula of [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-tert-butylheptanoate.

Fig.2 shows the formula of [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Atorvastatin calcium).

Fig.3 demonstrates the X-Ray diffractogram of amorphous form of atorvastatin calcium wherein the horizontal axis presents  $2\theta$  and the vertical axis corresponds to peak intensity.

Atorvastatin calcium, the substance known by the chemical name [R-(R\*, R\*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt is a synthetic HMG-CoA reductase inhibitor which is used for the treatment of hyperlipidemia and hypercholesterolemia. Atorvastatin in the pharmaceutical compositions is usually prepared as its calcium salt since it enables atorvastatin to be conveniently formulated in the pharmaceutical formulations.

Process for the preparation of atorvastatin and key intermediates are disclosed in the US patent numbers: 5,003,080; 5,097,045; 5,103,024; 5,124,482; 5,149,837; 5,155,251; 5,216,174; 5,245,047; 5,248,793; 5,280,126; 5,342,952; 5,397,792. All these process give mixtures of crystalline and amorphous forms with unsuitable filtration and drying characteristics rendering them unsuitable for large scale production. Atorvastatin calcium can exist in an amorphous form or in one of the crystalline forms, which are disclosed in the patent applications WO 97/3958, WO

97/3959, WO 97/3960. These studies provided more favorable filtration and drying characteristics.

Atorvastatin calcium is the substance which is sparingly soluble in water, with pKa 4,5 and it has been found that the crystalline forms are less soluble than the amorphous form, which may cause problems in bioavailability of atorvastatin in the body. It is very important to ensure uniformity of the substance being employed in a pharmaceutical formulation.

There are basically two different known routes in the literature to prepare amorphous atorvastatin calcium;

(1) from the crystalline form of atorvastatin calcium, which comprise:

dissolving crystalline form of atorvastatin in a solvent and removing of solvent (US 6,087,511) or alternatively adding a non solvent and filtering the precipitated amorphous form (WO 97/03960, US 6,274,740, US 6,087,311, US 6,528,660).

(2) from a reaction mixture of an intermediate of atorvastatin calcium, which comprise:

(2i) hydrolysis of atorvastatin lactone and having atorvastatin calcium in a solvent such as halogenated hydrocarbons, aliphatic esters or aromatic hydrocarbon, adding an anti-solvent such as ether or non-polar hydrocarbons and filtering the desired amorphous atorvastatin calcium (WO 03/018547).

(2ii) A similar process is described in the 2i (WO03/018547), but the amorphous form is obtained from aqueous phase by filtration (WO02/083637, WO02/083638, WO02/059087).

We report here a process for the preparation of the amorphous atorvastatin calcium and hydrates thus consist of:

- a) dissolving atorvastatin tert-butyl ester (Figure 1) in a solvent,
- b) adding an aqueous alkaline or alkaline earth metal hydroxide solution to the reaction mixture,
- c) removing of the solvent,
- d) adding water and a water non soluble solvent,
- e) adding an aqueous calcium salt solution to the reaction mixture,
- f) separation of the phases and removing of the solvent to obtain desired amorphous atorvastatin calcium and hydrates thereof.

The process disclosed herein gives amorphous form of atorvastatin calcium in a simple process without interconversion of any crystalline form. Additional solvents are not necessary to precipitate amorphous form. Additionally to these, the problem of removal of water from the product is not observed.

### EXAMPLE

5 g of atorvastatin tert-butyl ester (Fig.1) was dissolved in 100 ml of methanol, and a solution of 0.390 g of NaOH / 15 ml of water was added. Reaction mixture was stirred for 1 h at 50°C. After 1 h, TLC showed no starting material (TLC was performed on silica plate, eluent: Hexane/ethyl acetate: 1/1). Methanol was removed under reduced pressure. 100 ml of water and 100 ml of ethyl acetate were added. A solution of 0.870 g of  $\text{Ca}(\text{CH}_3\text{COO})_2 \cdot \text{X H}_2\text{O}$  / 20 ml of water was added. Reaction mixture was stirred for 1 h at 50°C. Mixture was cooled to room temperature and the phases were separated. The organic phase was washed with 2X50 ml of water. The organic phase was concentrated under vacuo at 50 °C to give desired amorphous atorvastatin calcium.

## CLAIMS

1. An improved process for the preparation of amorphous atorvastatin calcium, having formula of Figure 2 which comprises;
  - i) dissolving atorvastatin tert-butyl ester having formula of Figure 1 in a solvent,
  - ii) adding an aqueous solution of alkaline or alkaline earth metal hydroxide,
  - iii) removing of the solvent,
  - iv) adding water and a water non soluble solvent,
  - v) adding an aqueous solution of a calcium salt,
  - vi) separation of the phases and removing of the solvent to obtain desired amorphous atorvastatin calcium and hydrates thereof.
2. The process of Claim 1i, wherein solvent is methanol.
3. The process of Claim 1ii wherein alkaline or alkaline earth metal hydroxide is sodium hydroxide.
4. The process of Claim 1iv wherein the solvent is ethyl acetate,
5. The process of Claim 1v wherein calcium salt is, calcium acetate.




Figure 1.




Figure 2.




Figure 3.

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D207/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/059087 A (LEK TOVARNA FARMACEVTSKIH ; SORSAK GORAZD (SL)) 1 August 2002 (2002-08-01) cited in the application page 6, line 18 - page 9, line 14; claim 1	1-5
Y	BAUMANN K L ET AL: "THE CONVERGENT SYNTHESIS OF CI-981, AN OPTICALLY ACTIVE, HIGHLY POTENT, TISSUE SELECTIVE INHIBITOR OF HMG-COA REDUCTASE" 21 April 1992 (1992-04-21), TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, PAGE(S) 2283-2284 , XP000608147 ISSN: 0040-4039 page 2284, line 1 - line 10  -/--	1-5



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 February 2004

Date of mailing of the international search report

19/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Von Daacke, A



## INTERNATIONAL SEARCH REPORT

PCT/TR 03/00062

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/083637 A (CADILA HEALTHCARE LTD ; PANDITA KANWAL (IN); AGARWAL VIRENDRA KUMAR (I) 24 October 2002 (2002-10-24) cited in the application page 5, line 1 - page 8, line 25; claim 1	1-5
Y	US 6 087 511 A (LIN MIN ET AL) 11 July 2000 (2000-07-11) cited in the application claim 1	1-5
E	WO 03/068739 A (STACH JAN ; LECIVA A S (CZ); RADL STANISLAV (CZ)) 21 August 2003 (2003-08-21) page 5, line 16 - line 31; claim 1; examples 1-3	1-5

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02059087	A	01-08-2002	SI 20814 A	31-08-2002
			CA 2435954 A1	01-08-2002
			CZ 20031988 A3	12-11-2003
			EE 200300333 A	15-10-2003
			HU 0302797 A2	28-11-2003
			WO 02059087 A1	01-08-2002
			SK 9082003 A3	02-12-2003
			US 2003109569 A1	12-06-2003
WO 02083637	A	24-10-2002	WO 02083637 A1	24-10-2002
			WO 02083638 A1	24-10-2002
US 6087511	A	11-07-2000	AT 199542 T	15-03-2001
			AU 700794 B2	14-01-1999
			AU 6497896 A	18-02-1997
			BG 63631 B1	31-07-2002
			BG 102188 A	31-08-1998
			BR 9609714 A	23-02-1999
			CA 2220455 A1	06-02-1997
			DE 69611999 D1	12-04-2001
			DE 69611999 T2	26-07-2001
			DK 839132 T3	09-04-2001
			EA 625 B1	29-12-1999
			EE 9700369 A	15-06-1998
			EP 0839132 A1	06-05-1998
			GR 3035859 T3	31-08-2001
			HK 1018054 A1	01-11-2002
			HU 220343 B	28-12-2001
			IL 122161 A	14-07-1999
			JP 11510486 T	14-09-1999
			NO 980209 A	16-01-1998
			NZ 313008 A	28-01-2000
			SI 839132 T1	30-06-2001
			SK 5898 A3	05-08-1998
WO 03068739	A	21-08-2003	CZ 20020413 A3	15-10-2003
			WO 03068739 A1	21-08-2003